Αρχική World News FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A... World News FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation Από Ogkologos - 10 Δεκεμβρίου, 2024 985 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... 3 Δεκεμβρίου, 2024 Farmer With Stage IV Cancer Is Too Sick To Harvest Crops... 23 Ιανουαρίου, 2020 Immunotherapy Effective in Alveolar Soft Part Sarcoma 9 Ιανουαρίου, 2019 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz 12 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tebentafusp EMA Recommends Extension of Therapeutic Indications for Osimertinib Opinion: The Government should not be choosing between investing in staff... EMA Recommends Extension of Indications for Blinatumomab